TBC1D17

TBC1D17 is a Rab GTPase-activating protein (RabGAP) that controls distinct membrane trafficking and autophagic pathways by catalytically inactivating specific Rab GTPases (PMID:17562788, PMID:22854040). It was first defined as a regulator of a discrete endosomal route, selectively governing Shiga toxin transport from the cell surface to the Golgi without affecting EGF uptake (PMID:17562788). As a GAP for Rab8, TBC1D17 is bridged to its target by the adaptor optineurin, which binds a non-catalytic region of TBC1D17; this Rab8 inactivation blocks Rab8 recruitment to recycling tubules and impairs transferrin receptor recycling, an effect amplified by the glaucoma-associated optineurin E50K mutation (PMID:22854040). Structural work resolved a ternary arrangement in which the optineurin coiled-coil and GTP-bound Rab8a engage the TBC domain, while the optineurin leucine-zipper and the TBC domain compete for active Rab8a (PMID:39374890). TBC1D17 also acts as a GAP for Rab5, regulating GLUT1, GLUT4, and transferrin receptor trafficking; AMPK phosphorylation at Ser168 drives an intramolecular contact between the N-terminal region and the TBC domain that auto-inhibits TBC1D17, raising Rab5 activity to promote GLUT4 translocation and glucose uptake (PMID:34045668). In autophagy, TBC1D17 localizes to autophagosomes and restrains autophagy flux through its catalytic activity, and it forms homo- and heterodimers with TBC1D15 to inhibit Rab7 at the mitochondria–isolation membrane interface during Parkin-driven mitophagy (PMID:24752605, PMID:24569479). SUMOylated FIS1 binds TBC1D17 under hypoxia, positioning it as a negative regulator of hypoxia-induced mitophagy downstream of the SENP3–FIS1 axis (PMID:39638786). Crystal structures of the TBC domain reveal a heart-like fold that dimerizes near catalytic residues, and a separate Rab-binding domain confers high-affinity Rab5a binding that the TBC domain alone cannot (PMID:39374890, PMID:41999088).

1. 2007 Medium

   Establishing whether TBC1D17 has a defined cellular substrate pathway, a functional screen placed it as a Rab GAP acting in a discrete retrograde endosome-to-Golgi route rather than a generic trafficking regulator.

   Evidence Functional screen of predicted human Rab GAPs using Shiga toxin and EGF uptake assays in cells

   PMID:17562788

   Open questions at the time

   • Specific Rab substrate not identified in this study
   • Selectivity for Shiga toxin over EGF route mechanistically unexplained
2. 2012 High

   To explain how TBC1D17 reaches a specific Rab, optineurin was identified as an adaptor that bridges TBC1D17 to Rab8, linking Rab8 inactivation to transferrin receptor recycling and to glaucoma-associated optineurin mutation.

   Evidence Co-IP, colocalization, catalytically inactive mutant rescue, shRNA knockdown, live-cell imaging of Rab8 and transferrin receptor

   PMID:22854040

   Open questions at the time

   • Structural basis of the TBC1D17–optineurin–Rab8 interaction not defined
   • Whether other adaptors target TBC1D17 to additional Rabs unknown
3. 2014 Medium

   Connecting TBC1D17 GAP activity to a degradative outcome, it was shown to localize to autophagosomes and to suppress autophagy flux, with knockdown rescuing E50K-induced cell death.

   Evidence shRNA knockdown, catalytically inactive mutant, autophagosome colocalization, autophagy flux and viability assays

   PMID:24752605

   Open questions at the time

   • Rab substrate at autophagosomes not pinned down in this study
   • How TBC1D17 is recruited to autophagosome membranes unclear
4. 2014 High

   Addressing how mitophagy membrane dynamics are controlled, TBC1D17 was shown to dimerize with TBC1D15 and inhibit Rab7 at the mitochondria–isolation membrane interface downstream of Parkin.

   Evidence Co-IP for dimer detection, Rab7 activity assays, autophagosome morphology analysis, epistasis with PINK1/Parkin

   PMID:24569479

   Open questions at the time

   • Relative GAP contribution of TBC1D17 versus TBC1D15 within the heterodimer not resolved
   • Recruitment mechanism to the mitochondrial interface not defined
5. 2021 High

   Revealing how TBC1D17 activity is regulated, AMPK phosphorylation at Ser168 was shown to trigger an auto-inhibitory intramolecular interaction, restraining Rab5 GAP activity to promote GLUT4 translocation and glucose uptake.

   Evidence In vitro AMPK phosphorylation, Ser168 mutagenesis, intramolecular interaction mapping, Rab5 activity and GLUT4 translocation assays in muscle

   PMID:34045668

   Open questions at the time

   • Whether AMPK regulation extends to Rab8/Rab7-dependent functions untested
   • Structural detail of the N-terminal/TBC autoinhibited state not determined
6. 2024 High

   Defining the architecture of the Rab8 module, structural and competition analyses showed optineurin and active Rab8a can form a ternary complex with the TBC domain, while the optineurin leucine-zipper and TBC domain compete for active Rab8a.

   Evidence Crystal structure of OPTN LZD/active Rab8a, pull-down and Co-IP binding assays, ALS-mutation mutagenesis

   PMID:39374890

   Open questions at the time

   • Full TBC1D17/optineurin/Rab8a ternary structure not solved
   • Functional consequence of the competitive binding in cells not quantified
7. 2024 Medium

   Identifying an additional regulatory input, SUMOylated FIS1 was found to bind TBC1D17 under hypoxia, positioning it as a fine-tuning negative regulator of hypoxia-induced mitophagy via the SENP3–FIS1 axis.

   Evidence Co-IP of SUMOylated FIS1 with TBC1D17 under hypoxia, mitophagy flux and cell death assays in patient-derived glioma stem-like cells

   PMID:39638786

   Open questions at the time

   • Direct versus SUMO-dependent binding interface on TBC1D17 not mapped
   • Whether the FIS1 interaction modulates GAP catalytic activity unknown
8. 2026 High

   Resolving the substrate-recognition logic, crystal structures of the TBC domain revealed a heart-shaped fold that dimerizes near catalytic residues, and binding mapping established a distinct Rab-binding domain as critical for high-affinity Rab5a interaction.

   Evidence X-ray crystallography of murine and human TBC domains plus in vitro Rab5a binding with truncation fragments

   PMID:41999088

   Open questions at the time

   • Structure of the RBD–Rab5a complex not determined
   • Functional role of TBC domain dimerization in catalysis untested

• It remains unresolved how the multiple Rab substrates (Rab5, Rab7, Rab8), adaptor and regulatory inputs (optineurin, AMPK, SUMOylated FIS1), and dimerization states are integrated to select among endosomal recycling, autophagy, and mitophagy outputs in a given cellular context.
• No unified model coordinating Rab5/Rab7/Rab8 GAP activities
• Context determinants of substrate choice unknown
• In vivo physiological phenotypes of TBC1D17 loss not characterized in the corpus